St Pharm Co Ltd
237690
Company Profile
Business description
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm’s business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical’s business and development of oligonucleotide therapeutics. The company’s products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
Contact
Teheran Road 78, Gangnam-gu
7F MSA Building
Daechi-dong
Seoul891-43
KORT: +82 25276385
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
704
Stocks News & Analysis
stocks
Are declining Chinese births a red flag for A2 Milk?
Demographic challenges in A2’s largest market lead to sell-off.
stocks
Is this ASX share a value trap or bargain?
Cost-cutting the priority as underlying asset values falling on deaf ears.
stocks
Goldman Sachs Earnings: Valuations remain stretched
We raise our fair value estimate for Goldman Sachs stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,055.34 | 7.24 | -0.09% |
| DAX 40 | 24,468.82 | 234.30 | -0.95% |
| Dow JONES (US) | 48,488.59 | 870.74 | -1.76% |
| FTSE 100 | 10,131.64 | 4.86 | 0.05% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 22,954.32 | 561.07 | -2.39% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,796.86 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |